
Intellectual Property - May 27, 2025
NextCell receives US patent
NextCell Pharma has announced the issuance of a US patent titled “MSC Prediction Algorithm” by the United States Patent and Trademark Office (USPTO).

Intellectual Property - May 12, 2025
Prolight receives new patent approval in the US
The US Patent and Trademark Office (USPTO) has granted Prolight a patent for the analytical unit and reaction chamber for the company’s point-of-care analysis system, MicroFlex, which is being developed by Prolight’s partner TTP (The Technology Partnership).

Intellectual Property - April 29, 2025
Diamyd Medical granted European patent
Diamyd Medical's patent application protecting the use of insulin-based antigens for the treatment of autoimmune diabetes in patients carrying the HLA DR4-DQ8 genetic marker will be granted by the European Patent Office (EPO).

Intellectual Property - April 23, 2025
BioArctic receives European patent for exidavnemab
The European Patent Office, EPO, has issued a decision to grant European patent for exidavnemab, a drug candidate being developed as a treatment for synucleinopathies such as Parkinson’s disease and Multiple System Atrophy (MSA).

Intellectual Property - April 23, 2025
SynAct Pharma receives Notice of Allowance for grant of US patent
The Unites States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application with claims covering a method of treating rheumatoid arthritis (RA) with resomelagon (AP1189) in combination with methotrexate (MTX).

Intellectual Property - March 14, 2025
QureTech Bio granted European patent for new class of antibacterials
The company has been granted a patent by the European Patent Office (EPO) for GmPcides, a new class of synthetic antibacterials.